Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 7/20 | 0.80 |
| ▸ | GSK3A | P49840 | 2/20 | 0.72 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.72 |
| ▸ | PNP | P00491 | 1/20 | 0.69 |
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | KRAS | P01116 | 6/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.60 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3812192 | 0.91 | HINT1 (0.67) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL15061595 | 0.91 | HINT1 (0.67) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL1611244 | 0.90 | HINT1 (0.77) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL4733243 | 0.90 | HINT1 (0.76) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL9295421 | 0.89 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL9295418 | 0.89 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| 2'-Beta-Methyl-Guanosine SCHEMBL11965261 | 0.89 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| 2'-Beta-Methyl-Guanosine SCHEMBL14178410 | 0.89 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| 2'-Beta-Methyl-Guanosine SCHEMBL15338533 | 0.89 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| 2'-Beta-Methyl-Guanosine SCHEMBL116165 | 0.89 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239991-A | Preparation process of high-purity 2-amino-6-chloropurine nucleoside | 甘肃省化工研究院有限责任公司 | 2024-06-25 | — | — | CN | claimed |
| CN-117886868-A | Preparation method of 5' -DMT nucleoside compound | 天津奥瑞芙生物医药有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-8088752-B2 | Methods for metabolic modulation | VDF FUTURECEUTICALS, INC. (US) | 2012-01-03 | — | — | US | claimed |
| EP-2089409-A1 | COMPOUND HAVING INHIBITORY ACTIVITY ON A RHO-GTPASE CELL PROTEIN, A PROCESS FOR OBTAINING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISION THEREOF AND A METHOD FOR THE TREATMENT OF A RHO-GTPASE CELL PROTEIN-MEDIATED CONDITION | Universidad Nacional De Quilmes (AR) | 2009-08-19 | — | — | EP | claimed |
| WO-2008055875-A1 | COMPOUND HAVING INHIBITORY ACTIVITY ON A RHO-GTPASE CELL PROTEIN, A PROCESS FOR OBTAINING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISION THEREOF AND A METHOD FOR THE TREATMENT OF A RHO-GTPASE CELL PROTEIN-MEDIATED CONDITION | UNIVERSIDAD NACIONAL DE QUILMES (AR) | 2008-05-15 | — | — | WO | claimed |
| US-12583882-B2 | Equatorially modified polymer linked multimers of guansine-3′, 5′-cyclic monophosphates | MIRECA MEDICINES GMBH (DE) | 2026-03-24 | — | — | US | disclosed |
| CN-119264184-B | Preparation method of dideoxy ring-opened ribonucleotide triphosphate and intermediate | 天津奥利芙生物技术有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119264184-A | Preparation method of dideoxy ring-opened ribonucleotide triphosphate and intermediate | 天津奥利芙生物技术有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-115109110-B | Initial capping oligonucleotide primer containing six-membered sugar ring structure, and preparation method and application thereof | 江苏申基生物科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118239991-A | Preparation process of high-purity 2-amino-6-chloropurine nucleoside | 甘肃省化工研究院有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-114853836-B | Initial capping oligonucleotide primer containing GNA structure and preparation method and application thereof | 江苏申基生物科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117886868-A | Preparation method of 5' -DMT nucleoside compound | 天津奥瑞芙生物医药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-0216860-B1 | STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS | SUMMERTON, James (US) | 1992-10-28 | — | — | EP | disclosed |
| US-5142047-A | Morpholino nucleosides for blocking targeted genetic sequence | ANTI-GENE DEVELOPMENT GROUP (US) | 1992-08-25 | — | — | US | disclosed |
| EP-0216860-A4 | STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS. | SUMMERTON JAMES (US) | 1989-02-22 | — | — | EP | disclosed |
| EP-0215942-A4 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. | SUMMERTON JAMES | 1988-08-23 | — | — | EP | disclosed |
| EP-0216860-A1 | STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS. | SUMMERTON JAMES (US) | 1987-04-08 | — | — | EP | disclosed |
| EP-0215942-A1 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. | SUMMERTON JAMES | 1987-04-01 | — | — | EP | disclosed |
| WO-1986005519-A1 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD | SUMMERTON JAMES | 1986-09-25 | — | — | WO | disclosed |
| WO-1986005518-A1 | STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS | SUMMERTON JAMES | 1986-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583882-B2 | Equatorially modified polymer linked multimers of guansine-3′, 5′-cyclic monophosphates | PDE7A, PRKG1, NT5C3B | HINT1 1260/4885GSK3A 308/4885RPS6KA3 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.